Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock

Turn Therapeutics Inc. (NASDAQ:TTRX) Director Arthur Golden acquired 20,532 shares of the company’s stock in a transaction on Friday, November 21st. The stock was bought at an average cost of $2.87 per share, with a total value of $58,926.84. Following the completion of the acquisition, the director directly owned 50,734 shares in the company, valued at approximately $145,606.58. This represents a 67.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Turn Therapeutics Price Performance

Shares of TTRX traded up $0.05 during trading hours on Monday, hitting $3.32. 18,004 shares of the company were exchanged, compared to its average volume of 776,973. Turn Therapeutics Inc. has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.